T2 Biosystems, Inc. TTOO
- Market cap
- $6.5M
- P/E
- 0.0×
Follow TTOO
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | 489.00 | 250.00 | 294.00 | 52.00 | 23.50 | 45.00 | 5.12 | 3.36 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | 1,130.00 | 699.00 | 998.00 | 538.00 | 231.00 | 379.00 | 292.50 | 210.99 |
High Price
|
|||
| — | — | 178 | 161 | 153 | 151 | 148 | 182 | 158 | 113 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | 4 | 5 | 11 | 8 | 18 | 28 | 22 | 7 |
Revenue
|
|||
| — | — | (68.43%) | (157.78%) | (46.70%) | (101.12%) | (17.37%) | 26.21% | 5.81% | (113.58%) |
Gross Margin
|
|||
| — | — | (55) | (62) | (51) | (59) | (47) | (49) | (62) | (50) |
EBT
|
|||
| — | — | (1,343.24%) | (1,337.93%) | (487.17%) | (707.93%) | (258.12%) | (175.50%) | (277.98%) | (696.19%) |
EBT Margin
|
|||
| — | — | (55) | (62) | (51) | (59) | (47) | (49) | (62) | (50) |
Net Income
|
|||
| — | — | 2 | 3 | 2 | 4 | 3 | 3 | 1 | 1 |
Depreciation
|
|||
| — | — | 784.62 | 729.06 | 1,296.30 | 915.93 | 746.09 | 882.33 | 437.35 | 2.76 |
Revenue/Sh
|
|||
| — | — | (10,500.00) | (9,449.30) | (6,300.00) | (6,500.00) | (1,950.00) | (1,550.00) | (1,228.00) | (19.19) |
Earnings/Sh
|
|||
| — | — | (8,931.15) | (7,455.94) | (4,955.31) | (4,984.73) | (1,778.40) | (1,222.45) | (992.73) | (18.44) |
Cash Flow/Sh
|
|||
| — | — | (1,055.19) | (386.87) | (73.21) | (83.63) | (32.92) | (14.47) | (6.65) | (0.07) |
Capex/Sh
|
|||
| — | — | (9,986.35) | (7,842.81) | (5,028.52) | (5,068.35) | (1,811.32) | (1,236.92) | (999.37) | (18.52) |
Free CF/Sh
|
|||
| — | — | 7,565.00 | 209.38 | 1,405.80 | (3,736.81) | 359.09 | (405.75) | (777.55) | (10.74) |
Book Value/Sh
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
Shares
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | 0.67 | 0.61 | 0.23 | 0.13 | 0.17 | 0.06 | 0.37 | 1.96 |
PS Ratio
|
|||
| — | — | 0.07 | 2.12 | 0.21 | 0.00 | 0.35 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | (7.47) | (7.98) | (4.56) | (0.97) | 0.33 | 0.61 | 2.13 | 0.76 |
EV/Sales
|
|||
| — | — | 0.59 | 0.74 | 1.18 | 0.18 | (0.14) | (0.44) | (0.93) | (0.11) |
EV/FCF
|
|||
| — | — | (46) | (48) | (40) | (45) | (43) | (39) | (51) | (48) |
Op' Cash Flow
|
|||
| — | — | (5) | (2) | (1) | (1) | (1) | 0 | 0 | 0 |
Capex
|
|||
| — | — | (52) | (50) | (41) | (46) | (44) | (39) | (51) | (48) |
FCF
|
|||
| — | — | 66 | (7) | 4 | (42) | 44 | 33 | 9 | (31) |
Working Cap'
|
|||
| — | — | 40 | 2 | 0 | 2 | 45 | 48 | 50 | — |
Total Debt
|
|||
| — | — | (33) | (40) | (50) | (9) | 3 | 16 | 39 | (16) |
Net Debt
|
|||
| — | — | 39 | 1 | 11 | (34) | 9 | (13) | (40) | (28) |
Sh' Equity
|
|||
| — | — | (62.14%) | (86.45%) | (85.85%) | (127.17%) | (87.01%) | (70.54%) | (131.41%) | (144.89%) |
ROA
|
|||
| — | — | (517.39%) | 0.00% | 0.00% | 0.00% | (219.57%) | (1,015.05%) | 0.00% | 0.00% |
ROIC
|
|||
| — | — | (127.04%) | (306.94%) | (803.85%) | 521.76% | 370.25% | 2,357.72% | 237.20% | 147.96% |
ROE
|
|||
T2 Biosystems, Inc. peers in Diagnostics & Research
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| XWEL XWELL, Inc. | $7.6M | 0.0× | Compare |
| NDRA ENDRA Life Sciences Inc. | $8.9M | 0.0× | Compare |
| BIAF bioAffinity Technologies, Inc. | $9.0M | 0.0× | Compare |
| ADVB Advanced Biomed Inc. | $10.4M | 1.3× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DMTKQ DermTech, Inc. | $3.3M | 0.0× | Compare |
| ISPC iSpecimen Inc. | $3.1M | 0.0× | Compare |
| NOTVQ Inotiv, Inc. | $2.8M | 0.0× | Compare |
| PMD Psychemedics Corporation | $15.7M | 0.0× | Compare |
T2 Biosystems, Inc. (TTOO) key facts
- T2 Biosystems, Inc. (TTOO) is a Diagnostics & Research company in the Healthcare sector.
- T2 Biosystems, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $7.2 million, down 67.8% from fiscal 2022.
- Return on equity was 148.0% and debt-to-equity 0.00.
T2 Biosystems, Inc. (TTOO) Latest News
3 Feb
T2 Biosystems, Inc. has announced its intent to wind down operations, indicating a significant shift in the company's direction. This decision comes amid ongoing financial challenges and a strategic reevaluation of its business model. The company plans to cease its operations and is exploring options for its assets, which may include selling or liquidating them. This move reflects the difficulties faced by T2 Biosystems in the competitive diagnostics market and the need to address its financial viability. The decision to wind down operations fundamentally alters the company's competitive position and long-term prospects.
21 Oct
T2 Biosystems, Inc. (TTOO) is advancing its product pipeline with several key initiatives planned for 2025, focusing on innovative diagnostic solutions aimed at improving patient outcomes. The company is strategically positioning itself to enhance its market presence and address unmet medical needs, which could lead to significant growth opportunities. The report outlines the anticipated product launches and strategic partnerships that are expected to drive the company's future performance. Major strategic moves and product launches are expected to significantly alter the company's trajectory and investor sentiment.
7 Jan
T2 Biosystems announces preliminary fourth quarter and full year 2024 financial results. The financial results may moderately influence the company's performance and competitive positioning.
17 Dec
T2 Biosystems has shipped its 250,000th sepsis test globally. The milestone achievement may impact the company's competitive positioning and financial performance.
16 Dec
T2 Biosystems extends capital equipment supplier agreement with Vizient, Inc. The extension of the agreement may moderately influence T2 Biosystems' competitive positioning and financial performance.
9 Dec
T2 Biosystems plans to license its technology for detecting sepsis-causing pathogens from whole blood to generate revenue and accelerate market adoption. Licensing technology to expand market reach and generate revenue can significantly impact T2 Biosystems' future growth and competitive positioning.
15 Nov
T2 Biosystems Inc reported a 34% revenue increase in Q3 2024, signed a distribution agreement with Cardinal Health, and is advancing product pipeline. However, faced a net loss and NASDAQ notice. Strategic partnerships, revenue growth, and operational improvements are expected to significantly impact T2 Biosystems' future performance.
14 Nov
T2 Biosystems announced their financial results for the third quarter of 2024. The financial results may moderately influence the company's performance and competitive positioning.
5 Nov
T2 Biosystems will report Q3 2024 financial results and business updates on November 14, 2024. The financial results and business updates may moderately influence key areas like financial performance and competitive positioning.
11 Oct
T2 Biosystems, Inc. discussed recent developments including an exclusive US agreement with Cardinal Health, collaboration with pRxcision, FDA clearances, and financial results in a business update call. The exclusive US agreement with Cardinal Health, collaboration with pRxcision, and FDA clearances are expected to have a significant impact on T2 Biosystems' future growth and market performance.
T2 Biosystems Inc (TTOO) reported a 35% increase in total revenue in Q3 2024, with positive developments in sepsis test panel revenue and strategic partnerships. The article highlights significant revenue growth, key partnerships, and regulatory advancements that could reshape T2 Biosystems' competitive position and financial performance.
9 Oct
Cardinal Health and T2 Biosystems entered into a distribution deal for sepsis diagnostics, boosting CAH stock. Distribution deal with T2 Biosystems likely to significantly impact CAH's future and market performance.
8 Oct
T2 Biosystems, Inc. and Prxcision, Inc. announce co-marketing collaboration for rapid direct-from-blood diagnostics and AI-powered decision support platform. Collaboration is expected to revolutionize infection management, combat antibiotic resistance, and drive significant growth opportunities.
T2 Biosystems will host a business update call on October 10, 2024, to discuss recent developments and address shareholder questions. The business update call may moderately influence key areas such as financial performance and competitive positioning.
7 Oct
T2 Biosystems partners with Cardinal Health to sell FDA-cleared diagnostics for sepsis detection in the US. The exclusive agreement with Cardinal Health is expected to significantly expand T2 Biosystems' access to the US hospital market.
T2 Biosystems achieved a 35% increase in total revenue in the third quarter of 2024, driven by growth in sepsis test revenue and instrument revenue. The company also announced key pipeline and clinical advancements. The significant revenue growth and advancements in product development are expected to have a major impact on T2 Biosystems' future performance and market positioning.
23 Sep
T2 Biosystems highlighted a new article in The Lancet discussing the limitations of blood culture and the potential of rapid culture-independent diagnostics to improve health outcomes. The article highlights the potential of T2 Biosystems' technology to advance the field of rapid diagnostics and improve global response to infectious diseases.
20 Sep
T2 Biosystems successfully defended a key patent for its direct-from-whole blood pathogen detection method in the European Union. The successful defense of the patent is a significant move that can impact the company's competitive positioning and future product innovation.
16 Sep
T2 Biosystems receives FDA clearance to market T2Candida Panel for pediatric patients, expanding market to over 200 children's hospitals in the US. FDA clearance for pediatric use expected to significantly impact T2 Biosystems' market performance and future growth.
9 Sep
T2 Biosystems plans to launch multiple direct-from-blood diagnostics for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris in the next 15 months. The company's new product pipeline progress is expected to significantly impact its future performance and market positioning.
27 Aug
T2 Biosystems to participate in H.C. Wainwright 26th Annual Global Investment Conference. Participation in the conference may moderately influence financial performance and competitive positioning.
1 Aug
T2 Biosystems, Inc. to attend two upcoming investor conferences in August 2024. Participation in investor conferences may moderately influence financial performance and competitive positioning.
30 Jul
T2 Biosystems reported record sepsis test sales in Q2 2024, benefiting from a shortage of blood culture media bottles by BD. The company is focused on accelerating sales, enhancing operations, and advancing its pipeline with new tests. The potential impact of record sales, strategic partnerships, and new product launches on T2 Biosystems' future growth and market performance is significant.
29 Jul
T2 Biosystems, Inc. announced record sepsis test revenue for the second quarter of 2024, with a 27% growth compared to the prior year period. The company achieved significant revenue growth and made strategic advancements that are expected to have a notable impact on its future performance.
T2 Biosystems expands commercial reach in Malaysia and Indonesia through exclusive distribution agreement. Expansion into new territories with high sepsis rates and potential for rapid detection technology to significantly impact company's growth and market performance.
T2 Biosystems Inc. reported a loss of $9.2 million in Q2 with a per-share loss of 66 cents and revenue of $2 million. The financial performance in Q2 may moderately influence T2 Biosystems' competitive positioning and financial performance.
22 Jul
T2 Biosystems will report Q2 2024 financial results and business updates on July 29, 2024. The financial results and business updates may moderately influence key areas like financial performance and competitive positioning.
25 Jun
T2 Biosystems expands commercial reach in Hong Kong and Macau through exclusive distribution agreement. Expansion into high-sepsis regions with rapid detection technology can significantly impact T2 Biosystems' market performance.
22 May
T2 Biosystems regained compliance with Nasdaq listing requirements. Regaining compliance with Nasdaq listing requirements may moderately influence key areas such as financial performance and market sentiment.
17 May
T2 Biosystems closed an $8 million private placement for the purchase and sale of shares and warrants. The private placement will provide working capital and support sales, marketing, manufacturing, and clinical development.